<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6763598</article-id><article-id pub-id-type="doi">10.3389/fimmu.2019.02260</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Seeking <italic>Flavivirus</italic> Cross-Protective Immunity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>dos Santos Franco</surname><given-names>Lorrany</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/808011/overview"/></contrib><contrib contrib-type="author"><name><surname>Gushi</surname><given-names>Let&#x000ed;cia Tsieme</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/67348/overview"/></contrib><contrib contrib-type="author"><name><surname>Luiz</surname><given-names>Wilson Barros</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amorim</surname><given-names>Jaime Henrique</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/712913/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laborat&#x000f3;rio de Agentes Infecciosos e Vetores, Programa de P&#x000f3;s-gradua&#x000e7;&#x000e3;o em Patologia Investigativa, Centro das Ci&#x000ea;ncias Biol&#x000f3;gicas e da Sa&#x000fa;de, Universidade Federal do Oeste da Bahia</institution>, <addr-line>Bahia</addr-line>, <country>Brazil</country></aff><aff id="aff2"><sup>2</sup><institution>Programa de P&#x000f3;s-gradua&#x000e7;&#x000e3;o em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz</institution>, <addr-line>Bahia</addr-line>, <country>Brazil</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Daniela Weiskopf, La Jolla Institute for Immunology (LJI), United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Sandeep Kumar Dhanda, La Jolla Institute for Immunology (LJI), United States; Daniel M. Altmann, Imperial College London, United Kingdom</p></fn><corresp id="c001">*Correspondence: Jaime Henrique Amorim <email>jaime.amorim@ufob.edu.br</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p></fn><fn fn-type="other" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>2260</elocation-id><history><date date-type="received"><day>29</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 dos Santos Franco, Gushi, Luiz and Amorim.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>dos Santos Franco, Gushi, Luiz and Amorim</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The Flavivirus genus is composed by viral serocomplexes with relevant global epidemiological impact. Many areas of the world present both, vector fauna and geographical conditions compatible with co-circulation, importing, emergence, and epidemics of flaviviruses of different serocomplexes. In this study, we aimed to identify both, immunological determinants and patterns of immune response possibly involved in flavivirus serocomplex cross-protection. We searched B and T cells epitopes which were thoroughly shown to be involved in flavivirus immunological control. Such epitopes were analyzed regarding their conservation, population coverage, and location along flavivirus polyprotein. We found that epitopes capable of eliciting flavivirus cross-protective immunity to a wide range of human populations are concentrated in proteins E, NS3, and NS5. Such identification of both, immunological determinants and patterns of immune response involved in flavivirus cross-protective immunity should be considered in future vaccine development. Moreover, cross-reactive epitopes presented in this work may be involved in dynamics of diseases caused by flaviviruses worldwide.</p></abstract><kwd-group><kwd>epitopes</kwd><kwd>flavivirus</kwd><kwd>serocomplex</kwd><kwd>cross-protection</kwd><kwd>immune response</kwd></kwd-group><counts><fig-count count="3"/><table-count count="5"/><equation-count count="0"/><ref-count count="64"/><page-count count="12"/><word-count count="7888"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The Flavivirus genus of the Flaviviridae family is composed by over than 70 viral species with relevant global epidemiological impact. Flaviviruses viral particles have icosahedral capsid, are enveloped and present a single stranded genomic RNA of positive sense (<xref rid="B1" ref-type="bibr">1</xref>). The entry of flaviviruses is mainly based on endocytosis mediated by clathrin-coated pits and transport by an endocytic compartment. The low-pH environment within endosomes triggers conformational changes in the envelope glycoprotein (E), leading to membrane fusion of the viral envelope with the endosomal membrane and subsequent release of the nucleocapsid into the cytosol. The genomic RNA is translated into a viral polyprotein, which is cleaved by viral and cellular proteases, to originate flavivirus proteins (<xref rid="B1" ref-type="bibr">1</xref>). Three of these proteins are structural components of viral particle, called structural proteins. The E protein is the major antigen of the viral envelope. In addition to E protein, flavivirus particles contains also another envelope protein (M) and the capsid protein (C) (<xref rid="B1" ref-type="bibr">1</xref>). The polyprotein also originates non-structural proteins, which are not present on viral particle, but have important roles in viral replication and pathogenesis. There are seven non-structural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B e NS5. After protein synthesis, the assembly of viral particles takes place in the endoplasmic reticulum. Immature viral particles are then sent to Golgi complex to be maturated by furin activity. Mature viral particles are then transported through vesicles to the plasma membrane and released by exocytosis (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>The <italic>Flavivirus</italic> genus is involved in important chapters of both, World and Brazilian epidemiology histories. <italic>Yellow fever virus</italic> (YFV), <italic>Dengue virus</italic> (DENV) and <italic>Zika virus</italic> (ZIKV) were sequentially imported to Brazil and South America. Cases of yellow fever, caused by YFV, were first reported in Brazil in 1685. Thousands of yellow fever cases were noticed until the beginning of the twentieth century, when the <italic>Aedes aegypti</italic> mosquitoe was identified as the main vector of the disease. Vector eradication together with vaccination contributed to elimination of yellow fever from Brazilian urban areas (<xref rid="B2" ref-type="bibr">2</xref>). In 1981, the first epidemic caused by DENV was confirmed in Brazil (<xref rid="B3" ref-type="bibr">3</xref>). Since then, many epidemics have reached the country, usually related to the introduction of a new serotype or the change of the dominant serotype in a given region (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Such flavivirus is responsible for approximately 390 million of infections annually by one of its four serotypes (DENV1-4) (<xref rid="B5" ref-type="bibr">5</xref>). Thus, DENV is considered as the flavivirus of highest epidemiologic relevance of the world. But recently, ZIKV which was a pathogen previously associated with mild infections in Africa and Asia, was associated to microcephaly and <italic>Guillain-Barr&#x000e9;</italic> syndrome in the Americas (<xref rid="B6" ref-type="bibr">6</xref>). The first cases of ZIKV infection were reported in early 2015, in the Brazilian Northeast. The virus was very quickly spreaded and 141 suspected cases of microcephaly were reported in Northeastern states, in addition to many cases of spontaneous abortions and stillbirths (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>). In 2016 yellow fever cases were reported again in Brazil, with a total of 1,127 cases and 331 confirmed deaths until April 2018 (<xref rid="B10" ref-type="bibr">10</xref>). There is a number of additional flaviviruses with worldwide epidemiological importance or which are highly pathogenic. Examples are <italic>West Nile virus</italic> (WNV), <italic>Japanese encephalitis virus</italic> (JEV), <italic>Saint Louis encephalitis virus</italic> (SLEV) and <italic>Rocio virus</italic> (ROCV) (<xref rid="B11" ref-type="bibr">11</xref>). Such pathogens are vector-borne viruses, which are capable of traveling over long distances, carried by both, the human and/or the arthropod hosts. The risk of importing, emergence and epidemics caused by additional flaviviruses is clear in both, Brazil and other tropical regions of the world.</p><p>Humoral immune response to flaviviruses is complex and is involved in both, viral clearance and pathogenesis. An exacerbation of the disease severity mediated by antibodies, known as antibody-dependent enhancement (ADE), is observed in some cases of DENV infection. Immunoglobulins produced in a first infection by a specific serotype cross-react with viral particles present in a second infection caused by a different serotype. Viral particles are targeted to Fc-&#x003b3; receptors bearing cells by non-neutralizing antibodies, which facilitates penetration and replication of DENV (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Increased viral replication leads to increased viral loads, exacerbated inflammation, increased release of inflammatory cytokines and vasoactive amines, a phenomenon known as cytokine storm (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). ADE has also been described between DENV and ZIKV <italic>in vitro</italic> (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>). This phenomenon does not explain by itself the occurrence of severe dengue, but contribute to it in a relevant way. Investigations on ADE between different species of flavivirus have been reported, both <italic>in vitro</italic> (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>) and <italic>in vivo</italic> (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Most of the residues exposed at the external surface of flaviviral envelope are not conserved and are specific to each virus. Antibodies directed against envelope proteins potently neutralize the autologous and closely related viruses only (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). This criterion of cross-neutralization by polyclonal antibodies has led to the classification of flaviviruses into serocomplexes (<xref rid="B22" ref-type="bibr">22</xref>). At present, the literature does not show evidence that antibodies are capable of conferring anti-flavivirus cross-protective immunity by themselves.</p><p>On the other hand, cellular immune responses to flaviviruses were shown to be involved in cross-protective immunity (<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). Non-structural proteins, especially NS3 and NS5, are the main targets of T cells involved in flavivirus cross-protection (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B29" ref-type="bibr">29</xref>). The use of such proteins as subunit vaccine antigens was well documented in the literature. However, such vaccines were not tested in a serocomplex cross-protection context. Recent reports showed the importance of non-structural proteins in autologous (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B32" ref-type="bibr">32</xref>) or heterologous protection (<xref rid="B23" ref-type="bibr">23</xref>), regarding immunization with live attenuated viruses or natural infections. In contrast to structural proteins, it seems there are conserved residues in non-structural proteins which are capable of eliciting flavivirus cross-protective T cell immunity.</p><p>The Americas, Africa, Middle East, South East Asia and Europe have at least one <italic>Flavivirus</italic> serocomplex in circulation (<xref rid="B23" ref-type="bibr">23</xref>). Many areas of the world present both, vector fauna and geographical conditions compatible with co-circulation, importing, emergence and epidemics of flaviviruses. The encounter with multiple flaviviruses in a lifetime is increasingly likely. However, flavivirus cross-protective immunity is not well understood. In this study we aimed to find both, immunological determinants, and patterns of immune response possibly involved in flavivirus cross-protective immunity. We searched B and T cells epitopes which were thoroughly shown to be involved in flavivirus immunological control. Such epitopes were analyzed regarding their conservation along with different flavivirus serocomplexes. The epitopes were also studied regarding their population coverage, considering HLA allele frequencies of different human populations. Finally, epitopes with highest conservancy and population coverage were studied regarding their position along flavivirus polyprotein. Results presented in this study indicate that epitopes capable of eliciting flavivirus cross-protective immunity to a wide range of human populations are concentrated in proteins E, NS3, and NS5. Such identification of both, immunological determinants and patterns of immune response involved in flavivirus cross-protective immunity should be considered in future vaccine development. In addition, cross-reactive epitopes presented in this work may be involved in dynamics of diseases caused by flaviviruses worldwide.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Study Design</title><p>In this study we aimed to find both, immunological determinants and patterns of immune response possibly involved in flavivirus cross-protective immunity. As shown in <xref ref-type="fig" rid="F1">Figure 1</xref>, we carried out a literature search of flavivirus epitopes involved in protective immunity. Such epitopes were analyzed with regard to their conservancy, population coverage and location in flavivirus polyprotein.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Study design.</p></caption><graphic xlink:href="fimmu-10-02260-g0001"/></fig></sec><sec><title>Flavivirus Polyprotein Database</title><p>A database was built with polyprotein sequences from flaviviruses of different serocomplexes isolated in different continents of the world. Viruses taken in consideration were those of highest epidemiological relevance in Brazil and worldwide: <italic>Dengue virus</italic> (DENV), <italic>Zika virus</italic> (ZIKV), <italic>Yellow fever virus</italic> (YFV), <italic>West Nile virus</italic> (WNV), <italic>Japanese encephalitis virus</italic> (JEV), <italic>Saint Louis encephalitis virus</italic> (SLEV), <italic>Rocio virus</italic> (ROCV), <italic>Cacipocore virus</italic> (CPCV), <italic>Ilh&#x000e9;us virus</italic> (ILHV), and <italic>Iguape virus</italic> (IGUV). Sequences in FASTA format were retrieved from the National Center for Biotechnology Information (NCBI) protein database from September-2017 to September-2018 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/">http://www.ncbi.nlm.nih.gov/protein/</ext-link>). We aimed to recover sequences from all listed flavivirus species, isolated in all continents, with a limit of three sequences per country of each viral species. We noticed that for some species there were few deposits. In these cases, all available sequences were selected. Additional criteria for selecting sequences were: (i) complete annotation of structural and non-structural proteins within deposited polyprotein sequence and (ii) absence of undefined amino acid into sequence. The database consisted of a total of 325 polyprotein amino acid sequences (<xref ref-type="supplementary-material" rid="SM1">Supplemental Material 1</xref>).</p></sec><sec><title>Search of T Cell Epitopes Involved in Flavivirus Protective Immunity</title><p>We carried out a literature search for reports of experimental characterization of protective epitopes. CD4<sup>+</sup> and CD8<sup>+</sup> T cell epitopes which were related to protective immune response to flavivirus were searched in reports available at Pubmed from September-2017 to September-2018 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>). Criteria for selecting research articles were: (i) evaluation of epitope binding to HLA; (ii) determination of cytokine production pattern for both, CD4<sup>+</sup> and CD8<sup>+</sup> T cells; (iii) use of at least two different methods for determining cytokine production pattern and (iv), clear association with control of flavivirus infection. This last criterion involves validation of epitopes associated with survival under challenge experiments using humanized animals (transgenic mice expressing HLA), control of viral load under challenge experiments using humanized animals, infection of humans without disease and identification of important epitopes in immune responses elicited by well-known protective vaccines. Words used in the search were: CD4<sup>+</sup> T cell, CD8<sup>+</sup> T cell, epitopes, protection, immunity, <italic>Dengue virus, Zika virus, Yellow Fever virus, West Nile virus, Japanese encephalitis virus, Saint Louis encephalitis virus, Rocio virus, Cacipocore virus, Ilheus virus</italic>, and <italic>Iguape virus</italic>.</p></sec><sec><title>Search of B Cell Epitopes Targeted by Neutralizing Antibodies</title><p>B cell epitopes were searched at Immune Epitope Database and Analysis Resource-IEDB (<ext-link ext-link-type="uri" xlink:href="http://www.iedb.org">http://www.iedb.org</ext-link>) (<xref rid="B34" ref-type="bibr">34</xref>). The search was carried out until September 30, 2018, using the following conditions: any epitope at the epitope field; flavivirus at the antigen field, humans in the host field; positive assays only, B cells assay, <italic>in vitro</italic> and/or <italic>in vivo</italic> neutralization and 3D structure at the assay field; any MHC restriction at the MHC restriction field and infectious disease at the disease field.</p></sec><sec><title>Conservancy Analysis of Selected Epitopes</title><p>The IEDB conservancy analysis tool (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/conservancy">http://tools.iedb.org/conservancy</ext-link>) was used to determine the conservancy of the selected epitopes among the flavivirus sequences in the database previously constructed, as previously described (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Only epitopes at least 90% conserved among all sequences were selected.</p></sec><sec><title>Population Coverage Analyses</title><p>Epitopes selected after conservancy analysis were submitted to population coverage analysis, by using the IEDB population coverage calculation tool (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/tools/population/iedb_input">http://tools.immuneepitope.org/tools/population/iedb_input</ext-link>), as previously described (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>).</p></sec><sec><title>Localization of Selected Epitopes Along Flavivirus Polyprotein</title><p>Epitopes with high conservancy were submitted to location analysis along flavivirus polyprotein. Preliminary localization was retrieved from NCBI annotations. Then, 3D protein models of E, NS3 and NS5, deposited at the Protein Data Bank- PDB (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>), were used for fine localization. Pymol (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/">http://www.pymol.org/</ext-link>) was used to highlight selected epitopes along the proteins 3D models, as previously described (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Selection and Localization of Epitopes Which Are Targets for Neutralizing Antibodies</title><p>From over than 2,000 epitopes retrieved from search carried out as described in materials and methods, 19 were selected after conservancy analyses. One of the epitopes is contained inside a larger epitope as a consensus, in the same location. Thus, 18 epitopes are shown in <xref rid="T1" ref-type="table">Table 1</xref>. Such epitopes are discontinuous. From these, seven epitopes were shown to be 100% conserved and were selected for structural analyses. All selected epitopes are located in flavivirus envelope glycoprotein, mainly in domains II and III, as shown in <xref ref-type="fig" rid="F2">Figure 2</xref>. Our results indicate that the seven neutralizing epitopes selected are highly conserved among flaviviruses and may be involved in cross-protection and restriction of virus circulation in some regions of the world.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Discontinuous B lymphocyte epitope selected from IEDB website and, posteriorly, chosen through conservancy analyzes using cut off &#x02265;90%.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitope ID<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Virus<xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitope sequence/location</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Conservancy (&#x02265;90%)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>100% identity<xref ref-type="table-fn" rid="TN3"><sup>c</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Protein location</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">110534</td><td valign="top" align="left" rowspan="1" colspan="1">WNV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, G104, G106</td><td valign="top" align="center" rowspan="1" colspan="1">99.67%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">161539</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, G106, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">99.34%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">178102</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, L107,G109</td><td valign="top" align="center" rowspan="1" colspan="1">99.67%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191061</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">T76, W101, G106, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">90.43%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191066</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, G106, F108</td><td valign="top" align="center" rowspan="1" colspan="1">99.67%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191060</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">T76, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">90.76%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191068</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">99.67%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191062</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">T76, W101, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">90.76%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191057</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">G78, W101, L107, F108</td><td valign="top" align="center" rowspan="1" colspan="1">99.67%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">238073</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">R99, G102, G106, L107</td><td valign="top" align="center" rowspan="1" colspan="1">99.34%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">504083</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">R73, G78, E79</td><td valign="top" align="center" rowspan="1" colspan="1">91.42%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">161528</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">K307, K310, L389</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">161534</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">T303, T329, G383</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">191056</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">G78, W101, F108</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">504090</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">W101, L107, G111</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">504074</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">N103, G104, G111</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">504080</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">G100, W101, F108</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">530626</td><td valign="top" align="left" rowspan="1" colspan="1">DENV</td><td valign="top" align="left" rowspan="1" colspan="1">D378, R379, W381</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td><td valign="top" align="left" rowspan="1" colspan="1">DENV1, DENV2, DENV3, DENV4, ZIKV, YFV, WNV</td><td valign="top" align="left" rowspan="1" colspan="1">E protein</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>a</label><p><italic>Number of epitope ID at IEDB website</italic>.</p></fn><fn id="TN2"><label>b</label><p><italic>Virus in which the epitope was described</italic>.</p></fn><fn id="TN3"><label>c</label><p><italic>Viruses in which epitopes have 100% identity</italic>.</p></fn></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>Structural analysis of highly conserved neutralizing epitopes in flaviviruses. <bold>(A)</bold> Model of DENV envelope glycoprotein arranged as a dimer [(<xref rid="B33" ref-type="bibr">33</xref>), PDB number 1UZG]. Domain I is shown in red, domain II is shown in yellow, and domain III is shown in blue, and the fusion loop is shown in green. <bold>(B)</bold> Overview of locations of the neutralizing epitopes in E protein. <bold>(C)</bold> Approximate view of locations of epitopes which are targets for neutralizing antibodies. Epitopes shown to be located in domain II are: G78, W101, F108 (shown in green), W101, L107, G111 (shown in cyan), N103, G104, G111 (shown in deepteal cyan) and G100, W101, F108 (shown in lime green). Note that these epitopes are overlapping and that are they concentrated at the fusion loop and share W101 and G111. Domain III presents the epitopes: T303, T329, G383 (shown in light pink), K307, K310, L389 (shown in hot pink) and D378, R379, W381 (shown in violet purple).</p></caption><graphic xlink:href="fimmu-10-02260-g0002"/></fig></sec><sec><title>Selection of T Cell Epitopes Which May Be Involved in Flavivirus Serocomplex Cross-Protective Immunity</title><p>Nineteen research articles were selected reporting 529 epitopes. Such antigen determinants were experimentally characterized and associated with protective immunity. From the 529 epitopes 15 were selected after conservancy analysis. All selected epitopes are class I HLA ligands. Their amino acid sequences, HLA ligands, locations and percent conservations are shown in <xref rid="T2" ref-type="table">Table 2</xref>. Three epitopes showed conservation higher than 99% among all flavivirus polyproteins analyzed. In addition, virus-specific identity was also analyzed and is shown in <xref rid="T3" ref-type="table">Table 3</xref>. Epitope identity was shown to be constant in most of cases for each flavivirus. Together, these results indicate that there are fifteen epitopes associated with protective immunity which are highly conserved among flavivirus serocomplexes.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>T cell epitopes selected from literature review as contributing to flavivirus control and showing at least 90% conservation in the polyprotein dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>References<xref ref-type="table-fn" rid="TN4"><sup>a</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitope</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>HLA allele<xref ref-type="table-fn" rid="TN5"><sup>b</sup></xref></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Protein<xref ref-type="table-fn" rid="TN6"><sup>c</sup></xref></bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Conservancy<xref ref-type="table-fn" rid="TN7"><sup>d</sup></xref></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Wen et al. (<xref rid="B24" ref-type="bibr">24</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="left" rowspan="1" colspan="1">B*07:02</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 1725&#x02013;1734</td><td valign="top" align="center" rowspan="1" colspan="1">91.08%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weiskopf et al. (<xref rid="B27" ref-type="bibr">27</xref>), Weiskopf et al. (<xref rid="B37" ref-type="bibr">37</xref>),<break/> Elong Ngono et al. (<xref rid="B38" ref-type="bibr">38</xref>), Weiskopf et al. (<xref rid="B39" ref-type="bibr">39</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="left" rowspan="1" colspan="1">B*07:02, B*35:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 1700&#x02013;1709</td><td valign="top" align="center" rowspan="1" colspan="1">91.08%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weiskopf et al. (<xref rid="B27" ref-type="bibr">27</xref>), Weiskopf et al. (<xref rid="B37" ref-type="bibr">37</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">DPASIAARGY</td><td valign="top" align="left" rowspan="1" colspan="1">B*35:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 1768&#x02013;1777</td><td valign="top" align="center" rowspan="1" colspan="1">91.69%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weiskopf et al. (<xref rid="B27" ref-type="bibr">27</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">DISEMGANF</td><td valign="top" align="left" rowspan="1" colspan="1">A*26:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 1887&#x02013;1895</td><td valign="top" align="center" rowspan="1" colspan="1">93.85%</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">KAKGSRAIW</td><td valign="top" align="left" rowspan="1" colspan="1">B*57:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 2962&#x02013;2970</td><td valign="top" align="center" rowspan="1" colspan="1">92.00%</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RFLEFEALGF</td><td valign="top" align="left" rowspan="1" colspan="1">A*23:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 2977&#x02013;2986</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">de Melo et al. (<xref rid="B40" ref-type="bibr">40</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">TDTTPFGQQRVFKEK</td><td valign="top" align="left" rowspan="1" colspan="1">B*39</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 345&#x02013;359</td><td valign="top" align="center" rowspan="1" colspan="1">100.00%</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">EFGKAKGSRAIWYMW</td><td valign="top" align="left" rowspan="1" colspan="1">B*15</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 465&#x02013;479</td><td valign="top" align="center" rowspan="1" colspan="1">99.69%</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">AKGSRAIWYMWLGAR</td><td valign="top" align="left" rowspan="1" colspan="1">B*15</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 469&#x02013;483</td><td valign="top" align="center" rowspan="1" colspan="1">99.69%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weiskopf et al. (<xref rid="B37" ref-type="bibr">37</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">LPVWLAYKVA</td><td valign="top" align="left" rowspan="1" colspan="1">B*35:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 2005&#x02013;2014</td><td valign="top" align="center" rowspan="1" colspan="1">93.85%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elong Ngono et al. (<xref rid="B38" ref-type="bibr">38</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">APTRVVASEM</td><td valign="top" align="left" rowspan="1" colspan="1">B*07:02</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 1700&#x02013;1709</td><td valign="top" align="center" rowspan="1" colspan="1">96.92%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weiskopf et al. (<xref rid="B39" ref-type="bibr">39</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">SRAIWYMWLGARFLE</td><td valign="top" align="left" rowspan="1" colspan="1">DRB1*01:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 2966&#x02013;2980</td><td valign="top" align="center" rowspan="1" colspan="1">94.15%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rivino et al. (<xref rid="B41" ref-type="bibr">41</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">GEAAGIFMTA</td><td valign="top" align="left" rowspan="1" colspan="1">B*40:06</td><td valign="top" align="left" rowspan="1" colspan="1">NS3 301&#x02013;315</td><td valign="top" align="center" rowspan="1" colspan="1">92.92%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duan et al. (<xref rid="B42" ref-type="bibr">42</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">WYMWLGARFL</td><td valign="top" align="left" rowspan="1" colspan="1">A*24:02</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 475&#x02013;484</td><td valign="top" align="center" rowspan="1" colspan="1">94.46%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Turtle et al. (<xref rid="B43" ref-type="bibr">43</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">MTTEDMLQVW</td><td valign="top" align="left" rowspan="1" colspan="1">B*58:01</td><td valign="top" align="left" rowspan="1" colspan="1">NS5 3336&#x02013;3345</td><td valign="top" align="center" rowspan="1" colspan="1">96.00%</td></tr></tbody></table><table-wrap-foot><fn id="TN4"><label>a</label><p><italic>References of experimental validation of epitopes involved in the protective immune response against flavivirus that presented &#x02265; 90% of conservation in Flavivirus polyprotein sequences analyzed</italic>.</p></fn><fn id="TN5"><label>b</label><p><italic>HLA alleles which bind the selected epitopes</italic>.</p></fn><fn id="TN6"><label>c</label><p><italic>Location of selected epitopes in flavivirus polyprotein. Numbers refer to starting and ending positions of epitopes into flavivirus polyprotein sequences. Proteins in which epitopes are located were also indicated</italic>.</p></fn><fn id="TN7"><label>d</label><p><italic>Percent conservation of epitopes flavivirus polyprotein dataset. A homology cut off of 90% was applied with regard to flavivirus polyprotein dataset</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Percent of identity of selected epitopes into species-specific polyprotein datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitopes sequences</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>DENV1</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>DENV 2</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>DENV3</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>DENV4</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>ZIKV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>YFV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>WNV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>SLEV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>JEV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>IGUV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>ILHV</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>ROCV</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM<xref ref-type="table-fn" rid="TN8"><sup>a</sup></xref><sup>,</sup>
<xref ref-type="table-fn" rid="TN9"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DPASIAARGY<xref ref-type="table-fn" rid="TN8"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">100%/90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DISEMGANF</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KAKGSRAIW</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RFLEFEALGF</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90&#x02013;100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TDTTPFGQQRVFKEK</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EFGKAKGSRAIWYMW</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AKGSRAIWYMWLGAR</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LPVWLAYKVA</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90&#x02013;100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVASEM</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SRAIWYMWLGARFLE</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93,33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33&#x02013;100%</td><td valign="top" align="center" rowspan="1" colspan="1">93.33%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GEAAGIFMTA</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WYMWLGARFL</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%/90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%/90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTTEDMLQVW</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">90%</td></tr></tbody></table><table-wrap-foot><p><italic>Only percent identities &#x02265;90% were indicated</italic>.</p><fn id="TN8"><label>a</label><p><italic>Epitopes experimentally validated by more than one research group. Repeated epitopes were removed from the table</italic>.</p></fn><fn id="TN9"><label>b</label><p><italic>Epitopes which share amino acid sequences, but are located in different positions of viral polyprotein</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Population Coverage Analyses of Conserved T Cell Epitopes</title><p>As shown in conservancy analyses, we selected fifteen epitopes with at least 90% identity among all flaviviruses. Such epitopes were shown to present relevant population coverages with regard to the most prevalent HLA alleles and main ethnicities in Brazil and United States, as shown in <xref rid="T4" ref-type="table">Table 4</xref>. In addition, population coverage for selected epitopes were shown to be also relevant for most of world regions, as shown in <xref rid="T5" ref-type="table">Table 5</xref>. Our results indicate that those highly conserved epitopes bind to HLA molecules of different human populations worldwide, with high population coverage.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Population coverage by ethnicity in Brazil and United States of America.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitopes sequences</bold></th><th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Brazil (62.30%)<xref ref-type="table-fn" rid="TN10"><sup>a</sup></xref></bold></th><th valign="top" align="center" colspan="8" style="border-bottom: thin solid #000000;" rowspan="1"><bold>United States of America (88%)<xref ref-type="table-fn" rid="TN10"><sup>a</sup></xref></bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Amerindian</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Caucasoid</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Mixed</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Mulatto</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Amerindian</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Asian</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Austronesian</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Black</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Caucasoid</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Hispanic</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Mestizo</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Polynesian</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">12.18%</td><td valign="top" align="center" rowspan="1" colspan="1">19.18%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">3.46%</td><td valign="top" align="center" rowspan="1" colspan="1">5.14%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">14.27%</td><td valign="top" align="center" rowspan="1" colspan="1">23.23%</td><td valign="top" align="center" rowspan="1" colspan="1">10.44%</td><td valign="top" align="center" rowspan="1" colspan="1">9.67%</td><td valign="top" align="center" rowspan="1" colspan="1">2.77%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">19.86%</td><td valign="top" align="center" rowspan="1" colspan="1">28.09%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">30.32%</td><td valign="top" align="center" rowspan="1" colspan="1">13.15%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">25.85%</td><td valign="top" align="center" rowspan="1" colspan="1">33.59%</td><td valign="top" align="center" rowspan="1" colspan="1">21.69%</td><td valign="top" align="center" rowspan="1" colspan="1">22.02%</td><td valign="top" align="center" rowspan="1" colspan="1">31.55%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DPASIAARGY</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">8.21%</td><td valign="top" align="center" rowspan="1" colspan="1">9.94%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">27.37%</td><td valign="top" align="center" rowspan="1" colspan="1">8.23%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">12.54%</td><td valign="top" align="center" rowspan="1" colspan="1">11.87%</td><td valign="top" align="center" rowspan="1" colspan="1">11.91%</td><td valign="top" align="center" rowspan="1" colspan="1">13.02%</td><td valign="top" align="center" rowspan="1" colspan="1">29.22%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DISEMGANF</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">7.26%</td><td valign="top" align="center" rowspan="1" colspan="1">4.84%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.65%</td><td valign="top" align="center" rowspan="1" colspan="1">7.37%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">2.91%</td><td valign="top" align="center" rowspan="1" colspan="1">5.79%</td><td valign="top" align="center" rowspan="1" colspan="1">5.59%</td><td valign="top" align="center" rowspan="1" colspan="1">4.72%</td><td valign="top" align="center" rowspan="1" colspan="1">23.24%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KAKGSRAIW</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.40%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.27%</td><td valign="top" align="center" rowspan="1" colspan="1">3.72%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.40%</td><td valign="top" align="center" rowspan="1" colspan="1">7.21%</td><td valign="top" align="center" rowspan="1" colspan="1">2.36%</td><td valign="top" align="center" rowspan="1" colspan="1">3.93%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RFLEFEALGF</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">10.32%</td><td valign="top" align="center" rowspan="1" colspan="1">7.94%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.24%</td><td valign="top" align="center" rowspan="1" colspan="1">0.56%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">20.25%</td><td valign="top" align="center" rowspan="1" colspan="1">3.04%</td><td valign="top" align="center" rowspan="1" colspan="1">6.90%</td><td valign="top" align="center" rowspan="1" colspan="1">4.53%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TDTTPFGQQRVFKEK</td><td valign="top" align="center" rowspan="1" colspan="1">35.68%</td><td valign="top" align="center" rowspan="1" colspan="1">3.17%</td><td valign="top" align="center" rowspan="1" colspan="1">9.75%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">21.89%</td><td valign="top" align="center" rowspan="1" colspan="1">3.40%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">2.71%</td><td valign="top" align="center" rowspan="1" colspan="1">3.34%</td><td valign="top" align="center" rowspan="1" colspan="1">12.62%</td><td valign="top" align="center" rowspan="1" colspan="1">16.68%</td><td valign="top" align="center" rowspan="1" colspan="1">14.78%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EFGKAKGSRAIWYMW</td><td valign="top" align="center" rowspan="1" colspan="1">22.91%</td><td valign="top" align="center" rowspan="1" colspan="1">14.41%</td><td valign="top" align="center" rowspan="1" colspan="1">17.55%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">9.99%</td><td valign="top" align="center" rowspan="1" colspan="1">24.90%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">24.57%</td><td valign="top" align="center" rowspan="1" colspan="1">15.22%</td><td valign="top" align="center" rowspan="1" colspan="1">14.70%</td><td valign="top" align="center" rowspan="1" colspan="1">14.86%</td><td valign="top" align="center" rowspan="1" colspan="1">30.06%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AKGSRAIWYMWLGAR</td><td valign="top" align="center" rowspan="1" colspan="1">22.91%</td><td valign="top" align="center" rowspan="1" colspan="1">14.41%</td><td valign="top" align="center" rowspan="1" colspan="1">17.55%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">9.99%</td><td valign="top" align="center" rowspan="1" colspan="1">24.90%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">24.57%</td><td valign="top" align="center" rowspan="1" colspan="1">15.22%</td><td valign="top" align="center" rowspan="1" colspan="1">14.70%</td><td valign="top" align="center" rowspan="1" colspan="1">14.86%</td><td valign="top" align="center" rowspan="1" colspan="1">30.06%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LPVWLAYKVA</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">8.21%</td><td valign="top" align="center" rowspan="1" colspan="1">9.94%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">27.37%</td><td valign="top" align="center" rowspan="1" colspan="1">8.23%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">12.54%</td><td valign="top" align="center" rowspan="1" colspan="1">11.87%</td><td valign="top" align="center" rowspan="1" colspan="1">11.91%</td><td valign="top" align="center" rowspan="1" colspan="1">13.02%</td><td valign="top" align="center" rowspan="1" colspan="1">29.22%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVASEM</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">12.18%</td><td valign="top" align="center" rowspan="1" colspan="1">19.18%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">3.46%</td><td valign="top" align="center" rowspan="1" colspan="1">5.14%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">14.27%</td><td valign="top" align="center" rowspan="1" colspan="1">23.23%</td><td valign="top" align="center" rowspan="1" colspan="1">10.44%</td><td valign="top" align="center" rowspan="1" colspan="1">9.67%</td><td valign="top" align="center" rowspan="1" colspan="1">2.77%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SRAIWYMWLGARFLE</td><td valign="top" align="center" rowspan="1" colspan="1">0.41%</td><td valign="top" align="center" rowspan="1" colspan="1">10.76%</td><td valign="top" align="center" rowspan="1" colspan="1">9.43%</td><td valign="top" align="center" rowspan="1" colspan="1">11.64%</td><td valign="top" align="center" rowspan="1" colspan="1">0.98%</td><td valign="top" align="center" rowspan="1" colspan="1">5.50%</td><td valign="top" align="center" rowspan="1" colspan="1">0.99%</td><td valign="top" align="center" rowspan="1" colspan="1">4.92%</td><td valign="top" align="center" rowspan="1" colspan="1">14.81%</td><td valign="top" align="center" rowspan="1" colspan="1">7.12%</td><td valign="top" align="center" rowspan="1" colspan="1">7.74%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GEAAGIFMTA</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">6.69%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.08%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.43%</td><td valign="top" align="center" rowspan="1" colspan="1">0.40%</td><td valign="top" align="center" rowspan="1" colspan="1">11.24%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WYMWLGARFL</td><td valign="top" align="center" rowspan="1" colspan="1">14.44%</td><td valign="top" align="center" rowspan="1" colspan="1">21.85%</td><td valign="top" align="center" rowspan="1" colspan="1">16.16%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">53.94%</td><td valign="top" align="center" rowspan="1" colspan="1">33.22%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">4.57%</td><td valign="top" align="center" rowspan="1" colspan="1">18.26%</td><td valign="top" align="center" rowspan="1" colspan="1">23.41%</td><td valign="top" align="center" rowspan="1" colspan="1">26.97%</td><td valign="top" align="center" rowspan="1" colspan="1">56.79%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTTEDMLQVW</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">4.15%</td><td valign="top" align="center" rowspan="1" colspan="1">4.35%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.59%</td><td valign="top" align="center" rowspan="1" colspan="1">11.70%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">7.01%</td><td valign="top" align="center" rowspan="1" colspan="1">1.70%</td><td valign="top" align="center" rowspan="1" colspan="1">2.59%</td><td valign="top" align="center" rowspan="1" colspan="1">1.78%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total coverage<xref ref-type="table-fn" rid="TN11"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">60.60%</td><td valign="top" align="center" rowspan="1" colspan="1">65.91%</td><td valign="top" align="center" rowspan="1" colspan="1">69.96%</td><td valign="top" align="center" rowspan="1" colspan="1">11.64%</td><td valign="top" align="center" rowspan="1" colspan="1">81.09%</td><td valign="top" align="center" rowspan="1" colspan="1">74.53%</td><td valign="top" align="center" rowspan="1" colspan="1">0.99%</td><td valign="top" align="center" rowspan="1" colspan="1">68.51%</td><td valign="top" align="center" rowspan="1" colspan="1">71.45%</td><td valign="top" align="center" rowspan="1" colspan="1">68.62%</td><td valign="top" align="center" rowspan="1" colspan="1">71.52%</td><td valign="top" align="center" rowspan="1" colspan="1">92.04%</td></tr></tbody></table><table-wrap-foot><fn id="TN10"><label>a</label><p><italic>Percent values between parentheses refer to total population coverage of all epitope combined in countries</italic>.</p></fn><fn id="TN11"><label>b</label><p><italic>Population coverage of the epitope set presented in table computed in combination for each ethnicity</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Population coverage of selected epitopes for populations of different regions of the world.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Epitopes</bold><break/><bold> sequences</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>North</bold><break/><bold> America</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Central</bold><break/><bold> America</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>South</bold><break/><bold> America</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Europe</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>East</bold><break/><bold> Africa</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>West</bold><break/><bold> Africa</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Central</bold><break/><bold> Africa</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>North</bold><break/><bold> Africa</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>South</bold><break/><bold> Africa</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Northeast</bold><break/><bold> Asia</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>South</bold><break/><bold> Asia</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>East</bold><break/><bold> Asia</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Southeast</bold><break/><bold> Asia</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Southwest</bold><break/><bold> Asia</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Oceania</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="center" rowspan="1" colspan="1">12.70%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">4.75%</td><td valign="top" align="center" rowspan="1" colspan="1">21.45%</td><td valign="top" align="center" rowspan="1" colspan="1">6.15%</td><td valign="top" align="center" rowspan="1" colspan="1">7.01%</td><td valign="top" align="center" rowspan="1" colspan="1">10.54%</td><td valign="top" align="center" rowspan="1" colspan="1">5.57%</td><td valign="top" align="center" rowspan="1" colspan="1">0.03%</td><td valign="top" align="center" rowspan="1" colspan="1">2.60%</td><td valign="top" align="center" rowspan="1" colspan="1">2.74%</td><td valign="top" align="center" rowspan="1" colspan="1">9.44%</td><td valign="top" align="center" rowspan="1" colspan="1">1.20%</td><td valign="top" align="center" rowspan="1" colspan="1">6.02%</td><td valign="top" align="center" rowspan="1" colspan="1">3.17%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVAAEM</td><td valign="top" align="center" rowspan="1" colspan="1">25.20%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">8.43%</td><td valign="top" align="center" rowspan="1" colspan="1">30.73%</td><td valign="top" align="center" rowspan="1" colspan="1">10.51%</td><td valign="top" align="center" rowspan="1" colspan="1">24.53%</td><td valign="top" align="center" rowspan="1" colspan="1">20.80%</td><td valign="top" align="center" rowspan="1" colspan="1">16.02%</td><td valign="top" align="center" rowspan="1" colspan="1">0.05%</td><td valign="top" align="center" rowspan="1" colspan="1">6.29%</td><td valign="top" align="center" rowspan="1" colspan="1">8.62%</td><td valign="top" align="center" rowspan="1" colspan="1">22.01%</td><td valign="top" align="center" rowspan="1" colspan="1">3.76%</td><td valign="top" align="center" rowspan="1" colspan="1">11.28%</td><td valign="top" align="center" rowspan="1" colspan="1">5.37%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DPASIAARGY</td><td valign="top" align="center" rowspan="1" colspan="1">13.41%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">3.78%</td><td valign="top" align="center" rowspan="1" colspan="1">10.50%</td><td valign="top" align="center" rowspan="1" colspan="1">4.51%</td><td valign="top" align="center" rowspan="1" colspan="1">18.20%</td><td valign="top" align="center" rowspan="1" colspan="1">10.86%</td><td valign="top" align="center" rowspan="1" colspan="1">10.77%</td><td valign="top" align="center" rowspan="1" colspan="1">0.02%</td><td valign="top" align="center" rowspan="1" colspan="1">3.74%</td><td valign="top" align="center" rowspan="1" colspan="1">5.96%</td><td valign="top" align="center" rowspan="1" colspan="1">13.23%</td><td valign="top" align="center" rowspan="1" colspan="1">2.58%</td><td valign="top" align="center" rowspan="1" colspan="1">5.44%</td><td valign="top" align="center" rowspan="1" colspan="1">2.24%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DISEMGANF</td><td valign="top" align="center" rowspan="1" colspan="1">5.35%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">1.95%</td><td valign="top" align="center" rowspan="1" colspan="1">7.73%</td><td valign="top" align="center" rowspan="1" colspan="1">1.91%</td><td valign="top" align="center" rowspan="1" colspan="1">5.83%</td><td valign="top" align="center" rowspan="1" colspan="1">2.20%</td><td valign="top" align="center" rowspan="1" colspan="1">2.45%</td><td valign="top" align="center" rowspan="1" colspan="1">0.01%</td><td valign="top" align="center" rowspan="1" colspan="1">4.15%</td><td valign="top" align="center" rowspan="1" colspan="1">8.55%</td><td valign="top" align="center" rowspan="1" colspan="1">12.73%</td><td valign="top" align="center" rowspan="1" colspan="1">5.68%</td><td valign="top" align="center" rowspan="1" colspan="1">8.61%</td><td valign="top" align="center" rowspan="1" colspan="1">2.31%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KAKGSRAIW</td><td valign="top" align="center" rowspan="1" colspan="1">3.36%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.98%</td><td valign="top" align="center" rowspan="1" colspan="1">6.24%</td><td valign="top" align="center" rowspan="1" colspan="1">1.77%</td><td valign="top" align="center" rowspan="1" colspan="1">1.65%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">2.78%</td><td valign="top" align="center" rowspan="1" colspan="1">0.02%</td><td valign="top" align="center" rowspan="1" colspan="1">1.42%</td><td valign="top" align="center" rowspan="1" colspan="1">4.90%</td><td valign="top" align="center" rowspan="1" colspan="1">0.37%</td><td valign="top" align="center" rowspan="1" colspan="1">1.26%</td><td valign="top" align="center" rowspan="1" colspan="1">1.25%</td><td valign="top" align="center" rowspan="1" colspan="1">0.60%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RFLEFEALGF</td><td valign="top" align="center" rowspan="1" colspan="1">8.21%</td><td valign="top" align="center" rowspan="1" colspan="1">0.80%</td><td valign="top" align="center" rowspan="1" colspan="1">4.42%</td><td valign="top" align="center" rowspan="1" colspan="1">4.32%</td><td valign="top" align="center" rowspan="1" colspan="1">14.89%</td><td valign="top" align="center" rowspan="1" colspan="1">27.50%</td><td valign="top" align="center" rowspan="1" colspan="1">18.14%</td><td valign="top" align="center" rowspan="1" colspan="1">19.40%</td><td valign="top" align="center" rowspan="1" colspan="1">0.07%</td><td valign="top" align="center" rowspan="1" colspan="1">0.97%</td><td valign="top" align="center" rowspan="1" colspan="1">1.15%</td><td valign="top" align="center" rowspan="1" colspan="1">0.58%</td><td valign="top" align="center" rowspan="1" colspan="1">0.11%</td><td valign="top" align="center" rowspan="1" colspan="1">5.21%</td><td valign="top" align="center" rowspan="1" colspan="1">1.35%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TDTTPFGQQRVFKEK</td><td valign="top" align="center" rowspan="1" colspan="1">8.62%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">22.55%</td><td valign="top" align="center" rowspan="1" colspan="1">4.12%</td><td valign="top" align="center" rowspan="1" colspan="1">2.99%</td><td valign="top" align="center" rowspan="1" colspan="1">2.55%</td><td valign="top" align="center" rowspan="1" colspan="1">1.61%</td><td valign="top" align="center" rowspan="1" colspan="1">7.22%</td><td valign="top" align="center" rowspan="1" colspan="1">0.01%</td><td valign="top" align="center" rowspan="1" colspan="1">3.63%</td><td valign="top" align="center" rowspan="1" colspan="1">1.53%</td><td valign="top" align="center" rowspan="1" colspan="1">7.06%</td><td valign="top" align="center" rowspan="1" colspan="1">9.06%</td><td valign="top" align="center" rowspan="1" colspan="1">7.36%</td><td valign="top" align="center" rowspan="1" colspan="1">6.76%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EFGKAKGSRAIWYMW</td><td valign="top" align="center" rowspan="1" colspan="1">19.66%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">25.68%</td><td valign="top" align="center" rowspan="1" colspan="1">12.71%</td><td valign="top" align="center" rowspan="1" colspan="1">25.37%</td><td valign="top" align="center" rowspan="1" colspan="1">26.83%</td><td valign="top" align="center" rowspan="1" colspan="1">17.15%</td><td valign="top" align="center" rowspan="1" colspan="1">15.84%</td><td valign="top" align="center" rowspan="1" colspan="1">0.15%</td><td valign="top" align="center" rowspan="1" colspan="1">48.92%</td><td valign="top" align="center" rowspan="1" colspan="1">18.16%</td><td valign="top" align="center" rowspan="1" colspan="1">26.01%</td><td valign="top" align="center" rowspan="1" colspan="1">31.42%</td><td valign="top" align="center" rowspan="1" colspan="1">12.26%</td><td valign="top" align="center" rowspan="1" colspan="1">28.69%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AKGSRAIWYMWLGAR</td><td valign="top" align="center" rowspan="1" colspan="1">19.66%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">25.68%</td><td valign="top" align="center" rowspan="1" colspan="1">12.71%</td><td valign="top" align="center" rowspan="1" colspan="1">25.37%</td><td valign="top" align="center" rowspan="1" colspan="1">26.83%</td><td valign="top" align="center" rowspan="1" colspan="1">17.15%</td><td valign="top" align="center" rowspan="1" colspan="1">15.84%</td><td valign="top" align="center" rowspan="1" colspan="1">0.15%</td><td valign="top" align="center" rowspan="1" colspan="1">48.92%</td><td valign="top" align="center" rowspan="1" colspan="1">18.16%</td><td valign="top" align="center" rowspan="1" colspan="1">26.01%</td><td valign="top" align="center" rowspan="1" colspan="1">31.42%</td><td valign="top" align="center" rowspan="1" colspan="1">12.26%</td><td valign="top" align="center" rowspan="1" colspan="1">28.69%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LPVWLAYKVA</td><td valign="top" align="center" rowspan="1" colspan="1">13.41%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">3.78%</td><td valign="top" align="center" rowspan="1" colspan="1">10.50%</td><td valign="top" align="center" rowspan="1" colspan="1">4.51%</td><td valign="top" align="center" rowspan="1" colspan="1">18.20%</td><td valign="top" align="center" rowspan="1" colspan="1">10.86%</td><td valign="top" align="center" rowspan="1" colspan="1">10.77%</td><td valign="top" align="center" rowspan="1" colspan="1">0.02%</td><td valign="top" align="center" rowspan="1" colspan="1">3.74%</td><td valign="top" align="center" rowspan="1" colspan="1">5.96%</td><td valign="top" align="center" rowspan="1" colspan="1">13.23%</td><td valign="top" align="center" rowspan="1" colspan="1">2.58%</td><td valign="top" align="center" rowspan="1" colspan="1">5.44%</td><td valign="top" align="center" rowspan="1" colspan="1">2.24%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTRVVASEM</td><td valign="top" align="center" rowspan="1" colspan="1">12.70%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">4.75%</td><td valign="top" align="center" rowspan="1" colspan="1">21.45%</td><td valign="top" align="center" rowspan="1" colspan="1">6.15%</td><td valign="top" align="center" rowspan="1" colspan="1">7.01%</td><td valign="top" align="center" rowspan="1" colspan="1">10.54%</td><td valign="top" align="center" rowspan="1" colspan="1">5.57%</td><td valign="top" align="center" rowspan="1" colspan="1">0.03%</td><td valign="top" align="center" rowspan="1" colspan="1">2.60%</td><td valign="top" align="center" rowspan="1" colspan="1">2.74%</td><td valign="top" align="center" rowspan="1" colspan="1">9.44%</td><td valign="top" align="center" rowspan="1" colspan="1">1.20%</td><td valign="top" align="center" rowspan="1" colspan="1">6.02%</td><td valign="top" align="center" rowspan="1" colspan="1">3.17%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SRAIWYMWLGARFLE</td><td valign="top" align="center" rowspan="1" colspan="1">13.55%</td><td valign="top" align="center" rowspan="1" colspan="1">1.34%</td><td valign="top" align="center" rowspan="1" colspan="1">4.05%</td><td valign="top" align="center" rowspan="1" colspan="1">15.19%</td><td valign="top" align="center" rowspan="1" colspan="1">3.96%</td><td valign="top" align="center" rowspan="1" colspan="1">4.47%</td><td valign="top" align="center" rowspan="1" colspan="1">2.12%</td><td valign="top" align="center" rowspan="1" colspan="1">2.33%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">2.77%</td><td valign="top" align="center" rowspan="1" colspan="1">9.25%</td><td valign="top" align="center" rowspan="1" colspan="1">10.21%</td><td valign="top" align="center" rowspan="1" colspan="1">0.78%</td><td valign="top" align="center" rowspan="1" colspan="1">2.67%</td><td valign="top" align="center" rowspan="1" colspan="1">0.81%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GEAAGIFMTA</td><td valign="top" align="center" rowspan="1" colspan="1">0.22%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.11%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.41%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.72%</td><td valign="top" align="center" rowspan="1" colspan="1">0.03%</td><td valign="top" align="center" rowspan="1" colspan="1">3.11%</td><td valign="top" align="center" rowspan="1" colspan="1">14.14%</td><td valign="top" align="center" rowspan="1" colspan="1">8.33%</td><td valign="top" align="center" rowspan="1" colspan="1">2.06%</td><td valign="top" align="center" rowspan="1" colspan="1">5.32%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WYMWLGARFL</td><td valign="top" align="center" rowspan="1" colspan="1">22.87%</td><td valign="top" align="center" rowspan="1" colspan="1">0.00%</td><td valign="top" align="center" rowspan="1" colspan="1">23.76%</td><td valign="top" align="center" rowspan="1" colspan="1">17.38%</td><td valign="top" align="center" rowspan="1" colspan="1">2.38%</td><td valign="top" align="center" rowspan="1" colspan="1">5.04%</td><td valign="top" align="center" rowspan="1" colspan="1">2.00%</td><td valign="top" align="center" rowspan="1" colspan="1">8.00%</td><td valign="top" align="center" rowspan="1" colspan="1">0.04%</td><td valign="top" align="center" rowspan="1" colspan="1">24.09%</td><td valign="top" align="center" rowspan="1" colspan="1">16.66%</td><td valign="top" align="center" rowspan="1" colspan="1">49.65%</td><td valign="top" align="center" rowspan="1" colspan="1">40.08%</td><td valign="top" align="center" rowspan="1" colspan="1">10.29%</td><td valign="top" align="center" rowspan="1" colspan="1">52.33%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTTEDMLQVW</td><td valign="top" align="center" rowspan="1" colspan="1">4.66%</td><td valign="top" align="center" rowspan="1" colspan="1">1.40%</td><td valign="top" align="center" rowspan="1" colspan="1">1.40%</td><td valign="top" align="center" rowspan="1" colspan="1">1.45%</td><td valign="top" align="center" rowspan="1" colspan="1">11.14%</td><td valign="top" align="center" rowspan="1" colspan="1">8.44%</td><td valign="top" align="center" rowspan="1" colspan="1">6.51%</td><td valign="top" align="center" rowspan="1" colspan="1">5.93%</td><td valign="top" align="center" rowspan="1" colspan="1">0.02%</td><td valign="top" align="center" rowspan="1" colspan="1">7.68%</td><td valign="top" align="center" rowspan="1" colspan="1">9.08%</td><td valign="top" align="center" rowspan="1" colspan="1">3.75%</td><td valign="top" align="center" rowspan="1" colspan="1">13.27%</td><td valign="top" align="center" rowspan="1" colspan="1">5.13%</td><td valign="top" align="center" rowspan="1" colspan="1">2.59%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total Coverage<xref ref-type="table-fn" rid="TN12"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">74.17%</td><td valign="top" align="center" rowspan="1" colspan="1">3.50%</td><td valign="top" align="center" rowspan="1" colspan="1">67.96%</td><td valign="top" align="center" rowspan="1" colspan="1">69.60%</td><td valign="top" align="center" rowspan="1" colspan="1">58.61%</td><td valign="top" align="center" rowspan="1" colspan="1">73.78%</td><td valign="top" align="center" rowspan="1" colspan="1">55.97%</td><td valign="top" align="center" rowspan="1" colspan="1">60.88%</td><td valign="top" align="center" rowspan="1" colspan="1">0.30%</td><td valign="top" align="center" rowspan="1" colspan="1">74.77%</td><td valign="top" align="center" rowspan="1" colspan="1">66.06%</td><td valign="top" align="center" rowspan="1" colspan="1">84.70%</td><td valign="top" align="center" rowspan="1" colspan="1">74.75%</td><td valign="top" align="center" rowspan="1" colspan="1">54.27%</td><td valign="top" align="center" rowspan="1" colspan="1">73.66%</td></tr></tbody></table><table-wrap-foot><fn id="TN12"><label>a</label><p><italic>Population coverage of the epitope set presented in table computed in combination for each region of the world</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Localization of Selected T Cell Epitopes Along Flavivirus Polyprotein</title><p>All of selected epitopes were concentrated in flavivirus non-structural proteins 3 and 5 (NS3 and NS5, respectively). Thus, we used NS5 and NS3 3D models to study the locations of the epitopes. From fifteen epitopes, six were located in Helicase domain of the NS3 protein (NS3H), and eight were located in the RNA-dependent RNA polymerases domain of the NS5 protein (NS5p) (<xref ref-type="fig" rid="F3">Figure 3</xref>). These results indicate that NS3H and NS5p concentrate most of relevant T cell epitopes in the context of flavivirus cross-protective immunity.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Distribution of T cell epitopes &#x02265;90% conserved among flavivirus polyproteins. The locations of epitopes are shown in two different models: DENV NS3 protein <bold>(A,B)</bold> and ZIKV NS5 protein <bold>(C,D)</bold>. <bold>(A)</bold> The helicase domain of the DENV NS3 protein is shown in olive, while its protease domain is shown in chocolate brown. Six epitopes (shown in red) were shown to be located in NS3, all of them located in the protease domain. <bold>(B)</bold> Zoomed view of NS3 protein to detail epitopes. The numbers refer to the following epitopes, respectively: (<xref rid="B1" ref-type="bibr">1</xref>) APTRVVAAEM or APTRVVASEM, (<xref rid="B1" ref-type="bibr">1</xref>) APTRVVAAEM, (<xref rid="B2" ref-type="bibr">2</xref>) DPASIAARGY, (<xref rid="B3" ref-type="bibr">3</xref>) GEAAGIFMTA, (<xref rid="B4" ref-type="bibr">4</xref>) DISEMGANF, and (<xref rid="B5" ref-type="bibr">5</xref>) LPVWLAYKVA. <bold>(C)</bold> The methyltransferase domain of the NS5 protein is shown in light salmon, while its RNA polymerase domain is shown in slate blue. Eight epitopes (shown in red) were shown to be located in the NS5 protein, all of them in the RNA polymerase domain. <bold>(D)</bold> Approximate view of NS5 protein to detail epitopes. Some epitopes present overlapping. Thus, we show three different regions: Region 1 is composed by one epitope TDTTPFGQQRVFKEK. Region 2 contain six epitopes: KAKGSRAIW, RFLEFEALGF, EFGKAKGSRAIWYMW, AKGSRAIWYMWLGAR, SRAIWYMWLGARFLE, and WYMWLGARFL. Region 3 is composed of only one epitope: MTTEDMLQVW.</p></caption><graphic xlink:href="fimmu-10-02260-g0003"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this study, we aimed to identify both, immunological determinants and patterns of immune response possibly involved in flavivirus serocomplex cross-protection. Our premise was based on epidemiology of flaviviruses: most of them have both, vectoring and geographic conditions to co-circulate all together in the Americas, Africa, Asia and Oceania (<xref rid="B44" ref-type="bibr">44</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>). However, it does not happen. In addition, recent studies showed evidences of cross-protective immunity induced by vaccines or sequential infections (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>). We searched B and T cells epitopes, which were thoroughly shown to be involved in flavivirus infection control. We found a relevant number of epitopes which are capable of eliciting flavivirus protective immunity and are also highly conserved among serocomplexes. In addition, such epitopes cover a wide range of human populations and are concentrated in proteins E, NS3, and NS5. For such epitopes, mechanisms involved in virus control targeting the E protein are all related to antibody-mediated virus neutralization. On the other hand, mechanisms involved in virus control by targeting NS3 and NS5 proteins are mainly related to cytotoxicity mediated by CD8<sup>+</sup> T limphocytes.</p><p>The glycoprotein E is involved in binding of the viral particle to host cell receptors. In addition, such protein is also involved in membrane fusion. The E glycoprotein is arranged in three domains (DI, DII, and DIII). Domains I (DI) is central, surrounded by DII and DIII (<xref rid="B55" ref-type="bibr">55</xref>). The hydrophobic fusion loop is located in DII. It is highly conserved in flaviviruses serocomplexes due to its important role in mediating membrane fusion (<xref rid="B55" ref-type="bibr">55</xref>). The fusion loop has the same conformation in both protein forms trimer and dimer. In trimer, three amino acids are conserved in all flaviviruses (Trp 101, Leu 107, and Phe 108) and are exposed on molecular surface. Such amino acids have an important role in holding the fusion loop structure (<xref rid="B33" ref-type="bibr">33</xref>). Replacement of the Trp101 by an alanine prevents membrane fusion (<xref rid="B56" ref-type="bibr">56</xref>). In addition, natural infection by DENV was hypothesized to generate anti-DENV antibodies with cross-neutralizing activity against the fusion loop (<xref rid="B57" ref-type="bibr">57</xref>). All of discontinuous epitopes found in our study are located in E protein and most of them present these three conserved amino acids. We hypothesize that B cell epitopes presented in our study remain highly conserved across flavivirus serocomplexes due to their location at fusion loop.</p><p>The role of DIII in the flaviviral cycle is still unclear, although frequently related to a receptor binding function (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). It was previously shown that antibodies targeting different regions in DIII are able to strongly neutralize WNV. The regions are the N-terminal linker region (residues 302 to 309) and three strand-connecting loops, namely, BC (residues 330 to 333), DE (residues 365 to 368), and FG (residues 389 to 391) (<xref rid="B60" ref-type="bibr">60</xref>). In our study we found three discontinuous epitopes which are located in those regions: T303 T329 G383, K307 K310 L389, and D378 R379 W381. These epitopes revealed 100% conservancy among all 325 sequences analyzed. All of the selected B cell epitopes were show to be important in DENV neutralization (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B61" ref-type="bibr">61</xref>&#x02013;<xref rid="B63" ref-type="bibr">63</xref>). Of course, a physic validation regarding cross-neutralizing activity remains to be carried out. However, positions highlighted in <xref ref-type="fig" rid="F2">Figure 2</xref> are located in the same structures of flaviviruses with known envelope glycoprotein structure. Our results indicate that such epitopes are important targets to be considered in flavivirus serocomplex cross-immunity due to their key roles in viral life cycle.</p><p>With regard to conservation of T cell-specific immunological determinants among flavivirus serocomplexes, the YVF lost the highest amount of 100% conserved T cell epitopes (see <xref rid="T3" ref-type="table">Table 3</xref>). This is in accordance with the highest genetic distance of YFV serocomplex with regard to other flavivirus serocomplexes (<xref rid="B23" ref-type="bibr">23</xref>). An important explanation for the epidemiology of flaviviruses may arise from this observation. For example, vaccination against YFV in Brazil is not currently related to protection against DENV and ZIKV epidemics. However, DENV and JEV serocomplexes share most of epitopes identified in this work. It seems immunity to DENV precludes viruses of JEV serocomplex of circulating in South America. Recent studies showed evidences of cross-protective immunity between DENV and JEV serocomplexes (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B54" ref-type="bibr">54</xref>). The same does not occur in Central America, Africa and Asia. Interestingly, Central America and South Africa present a low population coverage of the selected T cell epitopes. Nevertheless, population coverage of class-I HLA specific epitopes presented in this work does not seem to explain the whole scenario. For example, the population of United States is 88% covered by the set of epitopes, but there is co-circulation of DENV and JEV serocomplexes in that country. In addition, most of regions in Africa and Asia, which have also a high population coverage of our set of epitopes, present co-circulation of DENV and JEV serocomplexes. The explanation for this is probably related to class-II HLA restricted epitopes, from which only two were selected according to our criteria. Such epitopes did not present a high conservation among all serocomplexes and probably confer cross-protection in specific combinations of viruses and serocomplexes, as previously described (<xref rid="B23" ref-type="bibr">23</xref>). It was recently shown that cross-reactive epitopes can promote recall from a pool of flavivirus serocomplex cross-reactive memory CD4<sup>+</sup> T cells (<xref rid="B23" ref-type="bibr">23</xref>). However, such epitopes are not enough conserved in order to induce cross-protection among all serocomplexes.</p><p>Cross-protective immunity into a given serocomplex seems to be more easily achieved (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>). Such cross-protection depends on recall of serocomplex cross-reactive memory CD4<sup>+</sup> T cells. There is not a high number of highly conserved class-II HLA restricted epitopes among all serocomplexes. Nevertheless, we identified two peptides capable of binding class-II HLA, involved in anti-YFV protective immune response which are highly conserved among all flavivirus serocomplexes. Thus, it seems achieving multivalent protection among serocomplexes depends on overcoming immunodominance. Highly conserved class-II HLA restricted epitopes do not seem to be immunodominant in order to promote recall of serocomplex cross-reactive memory CD4<sup>+</sup> T cells in a multivalent way.</p><p>With regard to class-I HLA restricted epitopes, we found fifteen highly conserved peptides which were thoroughly shown to be involved in flavivirus infection control. The peptides APTRVVAAEM, DPASIAARGY, DISEMGANF, KAKGSRAIW, and RFLEFEALGF are located in the NS3 or NS5 proteins. They bind to a subset of multifunctional CD8+ T limphocytes capable of producing IFN-&#x003b3; and TNF-&#x003b1; against DENV infection (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B27" ref-type="bibr">27</xref>). In addition, the peptide APTRVVAAEM is involved in cross-protection against DENV and ZIKV. The epitopes TDTTPFGQQRVFKEK, EFGKAKGSRAIWYMW, and AKGSRAIWYMWLGAR are concentrated in the NS5 protein and contain multiple HLA-I and -II binding motifs which are involved in elicitation of protective immune memory against YFV (<xref rid="B40" ref-type="bibr">40</xref>). The epitope MTTEDMLQVW is involved in protection against JEV (<xref rid="B43" ref-type="bibr">43</xref>). The remaining selected epitopes (see <xref rid="T2" ref-type="table">Table 2</xref>) were also related to protection against DENV. All of the selected epitopes are involved in induction of anti-flavivirus CD8<sup>+</sup> T cells. Some of the listed studies report generation os memory cells, which could also be recalled in order to favor cross-protective immunity.</p><p>Conserved epitopes could be enriched in artificial or natural immunizations. For example, sequential infection or administration of different anti-flavivirus vaccines would recall cross-reactive memory T CD4<sup>+</sup> and T CD8<sup>+</sup> lymphocytes. It is important to stress that approved vaccines represent three serocomplexes: DENV, JEV and YFV. However, most of those epitopes which are important for recalling cross-reactive T cells, are concentrated in non-structural proteins. The only anti-DENV vaccine currently approved for use in humans is a chimera between DENV and YFV. Its structural antigens are representative of DENV proteins, while non-structural antigens are representative of YFV proteins. In addition, the JEV vaccine is based on inactivated viruses. Enhancing the recall of cross-protective memory T cells would ideally happen with the use of live attenuated viruses or other vaccine approach capable of providing epitopes of non-structural proteins.</p></sec><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>All datasets generated for this study are included in the manuscript/<xref ref-type="sec" rid="s7">Supplementary Files</xref>.</p></sec><sec id="s6"><title>Author Contributions</title><p>JA conceived the study and wrote the paper. LS, LG, and WL analyzed data and wrote the paper.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We are grateful to FAPESB for providing undergraduation fellowship to LS. We are also grateful to CNPq for providing postdoc fellowship to LG.</p></ack><sec sec-type="supplementary-material" id="s7"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.02260/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2019.02260/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apte-Sengupta</surname><given-names>S</given-names></name><name><surname>Sirohi</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>RJ</given-names></name></person-group>. <article-title>Coupling of replication and assembly in flaviviruses</article-title>. <source>Curr Opin Virol</source>. (<year>2014</year>) <volume>9</volume>:<fpage>134</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.09.020</pub-id><?supplied-pmid 25462445?><pub-id pub-id-type="pmid">25462445</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="book"><source>Febre amarela: Guia para Profissionais da sa&#x000fa;de</source>. <edition>1st ed</edition>
<publisher-loc>Brasil</publisher-loc>: <publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de, Secretaria de Aten&#x000e7;&#x000e3;o &#x000e0; Sa&#x000fa;de</publisher-name> (<year>2017</year>).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="book"><source>Diretrizes Nacionais para a Preven&#x000e7;&#x000e3;o e Controle de Epidemias de Dengue</source>. <edition>1st ed</edition>
<publisher-loc>Brasil</publisher-loc>: <publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de, Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de, Departamento de Vigil&#x000e2;ncia Epidemiol&#x000f3;gica</publisher-name> (<year>2009</year>).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Veronesi</surname><given-names>F</given-names></name></person-group>
<source>Tratado de Infectologia</source>. <edition>5th Edn</edition>
<publisher-loc>S&#x000e3;o Paulo</publisher-loc>: <publisher-name>Atheneu</publisher-name> (<year>2015</year>).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Messina</surname><given-names>JP</given-names></name><name><surname>Farlow</surname><given-names>AW</given-names></name><name><surname>Moyes</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>The global distribution and burden of dengue</article-title>. <source>Nature</source>. (<year>2013</year>) <volume>496</volume>:<fpage>504</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature12060</pub-id><?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Areas with Zika|Zika virus|CDC</collab></person-group>
<source>Areas with Zika|Zika virus|CDC.</source> Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/zika/geo/">http://www.cdc.gov/zika/geo/</ext-link> (accessed March 15, 2016).</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Brito</surname><given-names>CAA</given-names></name><name><surname>Cordeiro</surname><given-names>MT</given-names></name></person-group>
<article-title>One year after the Zika virus outbreak in Brazil: from hypotheses to evidence</article-title>. <source>Rev Soc Bras Med Trop</source>. (<year>2016</year>) <volume>49</volume>:<fpage>537</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1590/0037-8682-0328-2016</pub-id><pub-id pub-id-type="pmid">27812646</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priyamvada</surname><given-names>L</given-names></name><name><surname>Quicke</surname><given-names>KM</given-names></name><name><surname>Hudson</surname><given-names>WH</given-names></name><name><surname>Onlamoon</surname><given-names>N</given-names></name><name><surname>Sewatanon</surname><given-names>J</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2016</year>) <volume>113</volume>:<fpage>7852</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1607931113</pub-id><?supplied-pmid 27354515?><pub-id pub-id-type="pmid">27354515</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wikan</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name></person-group>. <article-title>Zika virus: history of a newly emerging arbovirus</article-title>. <source>Lancet Infect Dis</source>. (<year>2016</year>) <volume>16</volume>:<fpage>e119</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30010-X</pub-id><?supplied-pmid 27282424?><pub-id pub-id-type="pmid">27282424</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mello</surname><given-names>M</given-names></name><name><surname>Rezende</surname><given-names>D</given-names></name><name><surname>Adelino</surname><given-names>R</given-names></name><name><surname>Alves</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>F</given-names></name><name><surname>Iani</surname><given-names>DM</given-names></name><etal/></person-group>
<article-title>Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018</article-title>. (<year>2018</year>) <volume>12</volume>:<fpage>e0006538</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0006538</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>Blaney</surname><given-names>JE</given-names></name><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name></person-group>. <article-title>Prospects for a dengue virus vaccine</article-title>. <source>Nat Rev Microbiol</source>. (<year>2007</year>) <volume>5</volume>:<fpage>518</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1690</pub-id><?supplied-pmid 17558424?><pub-id pub-id-type="pmid">17558424</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>AL</given-names></name></person-group>. <article-title>Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms</article-title>. <source>Nat Rev Immunol</source>. (<year>2011</year>) <volume>11</volume>:<fpage>532</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/nri3014</pub-id><?supplied-pmid 21760609?><pub-id pub-id-type="pmid">21760609</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanha</surname><given-names>PM</given-names></name><name><surname>Nascimento</surname><given-names>EJM</given-names></name><name><surname>Cynthia</surname><given-names>B</given-names></name><name><surname>Cordeiro</surname><given-names>MT</given-names></name><name><surname>de Carvalho</surname><given-names>OV</given-names></name><name><surname>de</surname><given-names>Mendon&#x000e7;a LR</given-names></name><etal/></person-group>
<article-title>Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) infection</article-title>. <source>J Infect Dis</source>. (<year>2016</year>) <volume>215</volume>:<fpage>781</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw638</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Wongwiwat</surname><given-names>W</given-names></name><name><surname>Rouvinski</surname><given-names>A</given-names></name><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name><name><surname>Duangchinda</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus</article-title>. <source>Nat Immunol</source>. (<year>2016</year>) <volume>17</volume>:<fpage>1102</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3515</pub-id><?supplied-pmid 27339099?><pub-id pub-id-type="pmid">27339099</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>LM</given-names></name><name><surname>Carlin</surname><given-names>ER</given-names></name><name><surname>Jenkins</surname><given-names>MM</given-names></name><name><surname>Tan</surname><given-names>AL</given-names></name><name><surname>Barcellona</surname><given-names>CM</given-names></name><name><surname>Nicholson</surname><given-names>CO</given-names></name><etal/></person-group>. <article-title>Dengue virus antibodies enhance Zika virus infection</article-title>. <source>Clin Transl Immunol</source>. (<year>2016</year>) <volume>5</volume>:<fpage>e117</fpage>. <pub-id pub-id-type="doi">10.1038/cti.2016.72</pub-id><?supplied-pmid 28090318?><pub-id pub-id-type="pmid">28090318</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansfield</surname><given-names>KL</given-names></name><name><surname>Horton</surname><given-names>DL</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Barrett</surname><given-names>ADT</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Flavivirus-induced antibody cross-reactivity</article-title>. <source>J Gen Virol</source>. (<year>2011</year>) <volume>92</volume>:<fpage>2821</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.031641-0</pub-id><?supplied-pmid 21900425?><pub-id pub-id-type="pmid">21900425</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terzian</surname><given-names>ACB</given-names></name><name><surname>Schanoski</surname><given-names>AS</given-names></name><name><surname>Mota de O</surname><given-names>MT</given-names></name><name><surname>da Silva</surname><given-names>RA</given-names></name><name><surname>Estofolete</surname><given-names>CF</given-names></name><name><surname>Colombo</surname><given-names>TE</given-names></name><etal/></person-group>
<article-title>Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed zika virus&#x02013;infected patients</article-title>. <source>Clin Infect Dis</source>. (<year>2017</year>) <volume>65</volume>:<fpage>1260</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix558</pub-id><pub-id pub-id-type="pmid">29017246</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raboni</surname><given-names>SM</given-names></name><name><surname>Bonfim</surname><given-names>C</given-names></name><name><surname>Almeida</surname><given-names>BM</given-names></name><name><surname>Zanluca</surname><given-names>C</given-names></name><name><surname>Koishi</surname><given-names>AC</given-names></name><name><surname>Rodrigues</surname><given-names>PRVP</given-names></name><etal/></person-group>. <article-title>Flavivirus cross-reactivity in serological tests and Guillain-Barr&#x000e9; syndrome in a hematopoietic stem cell transplant patient: a case report</article-title>. <source>Transpl Infect Dis</source>. (<year>2017</year>) <volume>19</volume>:<fpage>e12700</fpage>. <pub-id pub-id-type="doi">10.1111/tid.12700</pub-id><?supplied-pmid 28306183?><pub-id pub-id-type="pmid">28306183</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fibriansah</surname><given-names>G</given-names></name><name><surname>Lok</surname><given-names>SM</given-names></name></person-group>. <article-title>The development of therapeutic antibodies against dengue virus</article-title>. <source>Antiviral Res</source>. (<year>2016</year>) <volume>128</volume>:<fpage>7</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.01.002</pub-id><?supplied-pmid 26794397?><pub-id pub-id-type="pmid">26794397</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group>. <article-title>Molecular basis of antibody-mediated neutralization and protection against flavivirus</article-title>. <source>IUBMB Life</source>. (<year>2016</year>) <volume>68</volume>:<fpage>783</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1002/iub.1556</pub-id><?supplied-pmid 27604155?><pub-id pub-id-type="pmid">27604155</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>FA</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Vaney</surname><given-names>M</given-names></name><name><surname>Dellarole</surname><given-names>M</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name></person-group>. <article-title>The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design</article-title>. <source>EMBO Rep</source>. (<year>2017</year>) <volume>19</volume>:<fpage>e45302</fpage>. <pub-id pub-id-type="doi">10.15252/embr.201745302</pub-id><?supplied-pmid 29282215?><pub-id pub-id-type="pmid">29282215</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calisher</surname><given-names>CH</given-names></name><name><surname>Karabatsos</surname><given-names>N</given-names></name><name><surname>Dalrymple</surname><given-names>JM</given-names></name><name><surname>Shope</surname><given-names>RE</given-names></name><name><surname>Porterfield</surname><given-names>JS</given-names></name><name><surname>Westaway</surname><given-names>EG</given-names></name><etal/></person-group>. <article-title>Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera</article-title>. <source>J Gen Virol</source>. (<year>1989</year>) <volume>70</volume>(<issue>Pt 1</issue>):<fpage>37</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-70-1-37</pub-id><?supplied-pmid 2543738?><pub-id pub-id-type="pmid">2543738</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saron</surname><given-names>WAA</given-names></name><name><surname>Rathore</surname><given-names>APS</given-names></name><name><surname>Ting</surname><given-names>L</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Low</surname><given-names>J</given-names></name><name><surname>Abraham</surname><given-names>SN</given-names></name><etal/></person-group>. <article-title><italic>Flavivirus</italic> serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells</article-title>. <source>Sci Adv</source>. (<year>2018</year>) <volume>4</volume>:<fpage>eaar4297</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aar4297</pub-id><?supplied-pmid 29978039?><pub-id pub-id-type="pmid">29978039</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Sheets</surname><given-names>N</given-names></name><name><surname>Ellison</surname><given-names>J</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8(+) T cells</article-title>. <source>Nat Microbiol</source>. (<year>2017</year>) <volume>2</volume>:<fpage>17036</fpage>. <pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.36</pub-id><?supplied-pmid 28288094?><pub-id pub-id-type="pmid">28288094</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>CJ</given-names></name><name><surname>Suleyman</surname><given-names>OM</given-names></name><name><surname>Ortega-Prieto</surname><given-names>AM</given-names></name><name><surname>Skelton</surname><given-names>JK</given-names></name><name><surname>Bonnesoeur</surname><given-names>P</given-names></name><name><surname>Blohm</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other Flaviviruses</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>:<fpage>672</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-18781-1</pub-id><?supplied-pmid 29330423?><pub-id pub-id-type="pmid">29330423</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Elong Ngono</surname><given-names>A</given-names></name><name><surname>Viramontes</surname><given-names>KM</given-names></name><name><surname>Huynh</surname><given-names>AT</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><name><surname>Nguyen</surname><given-names>AVT</given-names></name><etal/></person-group>. <article-title>Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>3042</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-05458-0</pub-id><?supplied-pmid 30072692?><pub-id pub-id-type="pmid">30072692</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Bangs</surname><given-names>DJ</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes</article-title>. <source>J Virol</source>. (<year>2015</year>) <volume>89</volume>:<fpage>120</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02129-14</pub-id><?supplied-pmid 25320311?><pub-id pub-id-type="pmid">25320311</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Bangs</surname><given-names>DJ</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Kolla</surname><given-names>RV</given-names></name><name><surname>De Silva</surname><given-names>AD</given-names></name><name><surname>de Silva</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2015</year>) <volume>112</volume>:<fpage>E4256</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1505956112</pub-id><?supplied-pmid 26195744?><pub-id pub-id-type="pmid">26195744</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>Forni</surname><given-names>D</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Cagliani</surname><given-names>R</given-names></name></person-group>. <article-title>Nonstructural proteins are preferential positive selection targets in zika virus and related flaviviruses</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2016</year>) <volume>10</volume>:<fpage>e0004978</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0004978</pub-id><?supplied-pmid 27588756?><pub-id pub-id-type="pmid">27588756</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amorim</surname><given-names>JH</given-names></name><name><surname>dos Santos Alves</surname><given-names>RP</given-names></name><name><surname>Bizerra</surname><given-names>R</given-names></name><name><surname>Ara&#x000fa;jo Pereira</surname><given-names>S</given-names></name><name><surname>Ramos Pereira</surname><given-names>L</given-names></name><name><surname>Nascimento Fabris</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model</article-title>. <source>Virology</source>. (<year>2016</year>) <volume>487</volume>:<fpage>41</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.10.006</pub-id><pub-id pub-id-type="pmid">26496698</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivino</surname><given-names>L</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>Jovanovic</surname><given-names>V</given-names></name><name><surname>Nadua</surname><given-names>K</given-names></name><name><surname>Teo</surname><given-names>EW</given-names></name><name><surname>Pang</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<fpage>2693</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02675-12</pub-id><?supplied-pmid 23255803?><pub-id pub-id-type="pmid">23255803</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivino</surname><given-names>L</given-names></name><name><surname>Kumaran</surname><given-names>EA</given-names></name><name><surname>Thein</surname><given-names>T-L</given-names></name><name><surname>Too</surname><given-names>CT</given-names></name><name><surname>Hao Gan</surname><given-names>VC</given-names></name><name><surname>Hanson</surname><given-names>BJ</given-names></name><etal/></person-group>. <article-title>Virus-specific T lymphocytes home to the skin during natural dengue infection</article-title>. <source>Sci Transl Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>278ra35</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaa0526</pub-id><?supplied-pmid 25761891?><pub-id pub-id-type="pmid">25761891</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modis</surname><given-names>Y</given-names></name><name><surname>Ogata</surname><given-names>S</given-names></name><name><surname>Clements</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group>. <article-title>Structure of the dengue virus envelope protein after membrane fusion</article-title>. <source>Nature.</source> (<year>2004</year>) <volume>427</volume>:<fpage>313</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature02165</pub-id><?supplied-pmid 14737159?><pub-id pub-id-type="pmid">14737159</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>H-H</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Fusseder</surname><given-names>N</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group>. <article-title>Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines</article-title>. <source>BMC Bioinformatics</source>. (<year>2007</year>) <volume>8</volume>:<fpage>361</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-8-361</pub-id><?supplied-pmid 17897458?><pub-id pub-id-type="pmid">17897458</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>dos Santos Franco</surname><given-names>L</given-names></name><name><surname>Oliveira Vidal</surname><given-names>P</given-names></name><name><surname>Amorim</surname><given-names>JH</given-names></name></person-group>. <article-title><italic>In silico</italic> design of a Zika virus non-structural protein 5 aiming vaccine protection against zika and dengue in different human populations</article-title>. <source>J Biomed Sci</source>. (<year>2017</year>) <volume>24</volume>:<fpage>88</fpage>. <pub-id pub-id-type="doi">10.1186/s12929-017-0395-z</pub-id><?supplied-pmid 29169357?><pub-id pub-id-type="pmid">29169357</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>H-H</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Dinh</surname><given-names>K</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>MJ</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group>. <article-title>Predicting population coverage of T-cell epitope-based diagnostics and vaccines</article-title>. <source>BMC Bioinformatics</source>. (<year>2006</year>) <volume>7</volume>:<fpage>153</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-7-153</pub-id><?supplied-pmid 16545123?><pub-id pub-id-type="pmid">16545123</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>de Azeredo</surname><given-names>EL</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Fernando</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2013</year>) <volume>110</volume>:<fpage>E2046</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1305227110</pub-id><?supplied-pmid 23580623?><pub-id pub-id-type="pmid">23580623</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elong Ngono</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Joo</surname><given-names>Y</given-names></name><name><surname>King</surname><given-names>K</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Protective role of cross-reactive CD8 T cells against dengue virus infection</article-title>. <source>EbioMed.</source> (<year>2016</year>) <volume>13</volume>:<fpage>284</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.006</pub-id><?supplied-pmid 27746192?><pub-id pub-id-type="pmid">27746192</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Yauch</surname><given-names>LE</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>John</surname><given-names>DV</given-names></name><name><surname>Jason</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Insights into HLA restricted T cell responses in a novel mouse model of dengue virus infection point towards new implications for vaccine design</article-title>. <source>J Immunol.</source> (<year>2012</year>) <volume>187</volume>:<fpage>4268</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1101970</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Melo</surname><given-names>AB</given-names></name><name><surname>Nascimento</surname><given-names>EJM</given-names></name><name><surname>Braga-Neto</surname><given-names>U</given-names></name><name><surname>Dhalia</surname><given-names>R</given-names></name><name><surname>Silva</surname><given-names>AM</given-names></name><name><surname>Oelke</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs</article-title>. <source>PLoS Negl Trop Dis.</source> (<year>2013</year>) <volume>7</volume>:<fpage>e1938</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001938</pub-id><?supplied-pmid 23383350?><pub-id pub-id-type="pmid">23383350</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivino</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>Grotenbreg</surname><given-names>GM</given-names></name><name><surname>MacAry</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>191</volume>:<fpage>4010</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301507</pub-id><?supplied-pmid 24058176?><pub-id pub-id-type="pmid">24058176</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>ZL</given-names></name><name><surname>Liu</surname><given-names>HF</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>SN</given-names></name><name><surname>Yang</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>XY</given-names></name><etal/></person-group>. <article-title>Identification of conserved and HLA-A<sup>*</sup>2402-restricted epitopes in Dengue virus serotype 2</article-title>. <source>Virus Res</source>. (<year>2015</year>) <volume>196</volume>:<fpage>5</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.10.022</pub-id><?supplied-pmid 25449574?><pub-id pub-id-type="pmid">25449574</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Bali</surname><given-names>T</given-names></name><name><surname>Buxton</surname><given-names>G</given-names></name><name><surname>Chib</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Soni</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human T cell responses to Japanese encephalitis virus in health and disease</article-title>. <source>J Exp Med</source>. (<year>2016</year>) <volume>213</volume>:<fpage>1331</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20151517</pub-id><?supplied-pmid 27242166?><pub-id pub-id-type="pmid">27242166</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubler</surname><given-names>DJ</given-names></name><name><surname>St. John</surname><given-names>AL</given-names></name></person-group>
<article-title>Dengue Viruses*</article-title>. In: <source>Reference Module in Biomedical Sciences</source>. Elsevier (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/b978-0-12-801238-3.02556-3</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubler</surname><given-names>DJ</given-names></name></person-group>
<article-title>Dengue, Urbanization and globalization: the Unholy Trinity of the 21st Century</article-title>. <source>Trop Med Health</source>. (<year>2011</year>) <volume>39</volume>:<fpage>S3</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.2149/tmh.2011-S05</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chancey</surname><given-names>C</given-names></name><name><surname>Grinev</surname><given-names>A</given-names></name><name><surname>Volkova</surname><given-names>E</given-names></name><name><surname>Rios</surname><given-names>M</given-names></name></person-group>. <article-title>The global ecology and epidemiology of west nile virus</article-title>. <source>Biomed Res Int</source>. (<year>2015</year>) <volume>2015</volume>:<fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1155/2015/376230</pub-id><?supplied-pmid 25866777?><pub-id pub-id-type="pmid">25866777</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>G</given-names></name><name><surname>Hills</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Jacobson</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>C</given-names></name><name><surname>Hombach</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Estimated global incidence of Japanese encephalitis: <italic>Bull World Health Organ</italic></article-title>. (<year>2011</year>) <volume>89</volume>:<fpage>766</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.10.085233</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konishi</surname><given-names>E</given-names></name><name><surname>Kitai</surname><given-names>Y</given-names></name><name><surname>Tabei</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name></person-group>. <article-title>Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program</article-title>. <source>Vaccine</source>. (<year>2010</year>) <volume>28</volume>:<fpage>2664</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.008</pub-id><?supplied-pmid 20080072?><pub-id pub-id-type="pmid">20080072</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jentes</surname><given-names>ES</given-names></name><name><surname>Poumerol</surname><given-names>G</given-names></name><name><surname>Gershman</surname><given-names>MD</given-names></name><name><surname>Hill</surname><given-names>DR</given-names></name><name><surname>Lemarchand</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever</article-title>. <source>Lancet Infect Dis</source>. (<year>2011</year>) <volume>11</volume>:<fpage>622</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70147-5</pub-id><?supplied-pmid 21798462?><pub-id pub-id-type="pmid">21798462</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amarilla</surname><given-names>AA</given-names></name><name><surname>Fumagalli</surname><given-names>MJ</given-names></name><name><surname>Figueiredo</surname><given-names>ML</given-names></name><name><surname>Lima-Junior</surname><given-names>DS</given-names></name><name><surname>Santos-Junior</surname><given-names>NN</given-names></name><name><surname>Alfonso</surname><given-names>HL</given-names></name><etal/></person-group>. <article-title>Ilheus and Saint Louis encephalitis viruses elicit cross-protection against a lethal Rocio virus challenge in mice</article-title>. <source>PLoS ONE</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e0199071</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0199071</pub-id><?supplied-pmid 29897990?><pub-id pub-id-type="pmid">29897990</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadinegoro</surname><given-names>SR</given-names></name><name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name><name><surname>Capeding</surname><given-names>MR</given-names></name><name><surname>Deseda</surname><given-names>C</given-names></name><name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name><name><surname>Dietze</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Efficacy and long-term safety of a dengue vaccine in regions of endemic disease</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>373</volume>:<fpage>1195</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1506223</pub-id><?supplied-pmid 26214039?><pub-id pub-id-type="pmid">26214039</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabchareon</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Sirivichayakul</surname><given-names>C</given-names></name><name><surname>Limkittikul</surname><given-names>K</given-names></name><name><surname>Chanthavanich</surname><given-names>P</given-names></name><name><surname>Suvannadabba</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial</article-title>. <source>Lancet</source>. (<year>2012</year>) <volume>380</volume>:<fpage>1559</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61428-7</pub-id><?supplied-pmid 22975340?><pub-id pub-id-type="pmid">22975340</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>L</given-names></name><name><surname>Dayan</surname><given-names>GH</given-names></name><name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name><name><surname>Rivera</surname><given-names>DM</given-names></name><name><surname>Cunha</surname><given-names>R</given-names></name><name><surname>Deseda</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Efficacy of a tetravalent dengue vaccine in children in Latin America</article-title>. <source>N Engl J Med</source>. (<year>2014</year>) <volume>372</volume>:<fpage>141103114505002</fpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1411037</pub-id><?supplied-pmid 25365753?><pub-id pub-id-type="pmid">25365753</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sheng</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>19953</fpage>. <pub-id pub-id-type="doi">10.1038/srep19953</pub-id><?supplied-pmid 26818736?><pub-id pub-id-type="pmid">26818736</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockburn</surname><given-names>JJB</given-names></name><name><surname>Navarro Sanchez</surname><given-names>ME</given-names></name><name><surname>Fretes</surname><given-names>N</given-names></name><name><surname>Urvoas</surname><given-names>A</given-names></name><name><surname>Staropoli</surname><given-names>I</given-names></name><name><surname>Kikuti</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody</article-title>. <source>Structure</source>. (<year>2012</year>) <volume>20</volume>:<fpage>303</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2012.01.001</pub-id><?supplied-pmid 22285214?><pub-id pub-id-type="pmid">22285214</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>MN</given-names></name><name><surname>Sousa</surname><given-names>FJR</given-names></name><name><surname>Carneiro</surname><given-names>FA</given-names></name><name><surname>Castanho</surname><given-names>MARB</given-names></name><name><surname>Valente</surname><given-names>AP</given-names></name><name><surname>Almeida</surname><given-names>FCL</given-names></name><etal/></person-group>. <article-title>Interaction of the dengue virus fusion peptide with membranes assessed by NMR: the essential role of the envelope protein Trp101 for membrane fusion</article-title>. <source>J Mol Biol</source>. (<year>2009</year>) <volume>392</volume>:<fpage>736</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2009.07.035</pub-id><?supplied-pmid 19619560?><pub-id pub-id-type="pmid">19619560</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>de Alwis</surname><given-names>AR</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name><name><surname>Ibarra</surname><given-names>KD</given-names></name><name><surname>Kahle</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein</article-title>. <source>MBio</source>. (<year>2013</year>) <volume>4</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00873-13</pub-id><?supplied-pmid 24255124?><pub-id pub-id-type="pmid">24255124</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukupolvi-Petty</surname><given-names>S</given-names></name><name><surname>Austin</surname><given-names>SK</given-names></name><name><surname>Purtha</surname><given-names>WE</given-names></name><name><surname>Oliphant</surname><given-names>T</given-names></name><name><surname>Nybakken</surname><given-names>GE</given-names></name><name><surname>Schlesinger</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes</article-title>. <source>J Virol</source>. (<year>2007</year>) <volume>81</volume>:<fpage>12816</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00432-07</pub-id><?supplied-pmid 17881453?><pub-id pub-id-type="pmid">17881453</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crill</surname><given-names>WD</given-names></name><name><surname>Roehrig</surname><given-names>JT</given-names></name></person-group>. <article-title>Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells</article-title>. <source>J Virol</source>. (<year>2001</year>) <volume>75</volume>:<fpage>7769</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.16.7769-7773.2001</pub-id><?supplied-pmid 11462053?><pub-id pub-id-type="pmid">11462053</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nybakken</surname><given-names>GE</given-names></name><name><surname>Oliphant</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Burke</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name></person-group>. <article-title>Structural basis of West Nile virus neutralization by a therapeutic antibody</article-title>. <source>Nature</source>. (<year>2005</year>) <volume>437</volume>:<fpage>764</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature03956</pub-id><?supplied-pmid 16193056?><pub-id pub-id-type="pmid">16193056</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HE</given-names></name><name><surname>Tsai</surname><given-names>WY</given-names></name><name><surname>Liu</surname><given-names>IJ</given-names></name><name><surname>Li</surname><given-names>PC</given-names></name><name><surname>Liao</surname><given-names>MY</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2012</year>) <volume>6</volume>:<fpage>e1447</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001447</pub-id><?supplied-pmid 22235356?><pub-id pub-id-type="pmid">22235356</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>W-Y</given-names></name><name><surname>Lai</surname><given-names>C-Y</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Lin</surname><given-names>H-E</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Jumnainsong</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<fpage>12562</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00871-13</pub-id><?supplied-pmid 24027331?><pub-id pub-id-type="pmid">24027331</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion</article-title>. <source>MAbs</source>. (<year>2016</year>) <volume>8</volume>:<fpage>574</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1080/19420862.2016.1148850</pub-id><?supplied-pmid 26905804?><pub-id pub-id-type="pmid">26905804</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S-H</given-names></name><name><surname>Li</surname><given-names>X-F</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>Y-Q</given-names></name><name><surname>Yu</surname><given-names>X-D</given-names></name><etal/></person-group>. <article-title>Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus</article-title>. <source>Immunol Lett</source>. (<year>2011</year>) <volume>138</volume>:<fpage>156</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2011.04.003</pub-id><?supplied-pmid 21515306?><pub-id pub-id-type="pmid">21515306</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Chowdhury</surname><given-names>P</given-names></name><name><surname>Borah</surname><given-names>J</given-names></name><name><surname>Dutta</surname><given-names>P</given-names></name></person-group>
<article-title>Cross-protective immunity against circulating Japanese encephalitis virus and West Nile Virus by live attenuated Japanese encephalitis vaccine SA 14-14-2</article-title>. <source>Int J Infect Dis</source>. (<year>2016</year>) <volume>45</volume>:<fpage>434</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijid.2016.02.922</pub-id></mixed-citation></ref></ref-list></back></article>